Articles published by Alentis Therapeutics

Alentis and PinotBio Announce Collaboration to Develop Next-Generation ADCs Targeting claudin-1

October 14, 2026

From Alentis Therapeutics

Via Business Wire

Alentis Strengthens Management Team with Key Appointments

November 12, 2025

From Alentis Therapeutics

Via Business Wire

Alentis Appoints Mark Pruzanski as CEO

October 15, 2025

From Alentis Therapeutics

Via Business Wire

Alentis Announces Positive Topline Results from Two Studies of Lixudebart (ALE.F02) in Patients with ANCA-RPGN and Advanced Liver Fibrosis

January 09, 2025

From Alentis Therapeutics

Via Business Wire

Alentis Receives FDA Fast Track Designation for ALE.P02 for the Treatment of CLDN1+ Squamous Solid Tumors

November 18, 2024

From Alentis Therapeutics

Via Business Wire

Alentis Therapeutics Raises $181.4 Million in an Oversubscribed Series D Financing to Advance the Clinical Development of Anti-Claudin-1 ADCs in Solid Tumors

November 12, 2024

From Alentis Therapeutics

Via Business Wire

Alentis Therapeutics Receives FDA IND Clearance for ALE.P02, a Novel CLDN1-ADC for the Treatment of Squamous Cancers

October 02, 2024

From Alentis Therapeutics

Via Business Wire

Alentis Appoints Jonathan Freve CFO

September 03, 2024

From Alentis Therapeutics

Via Business Wire

Alentis Receives FDA Orphan Drug Designation for Lixudebart to Treat Idiopathic Pulmonary Fibrosis

May 29, 2024

From Alentis Therapeutics

Via Business Wire

Alentis Appoints Alberto Toso Chief Scientific Officer

April 29, 2024

From Alentis Therapeutics

Via Business Wire

William Pao Joins Alentis Therapeutics as Independent Board Member

January 08, 2024

From Alentis Therapeutics

Via Business Wire

Alentis Therapeutics Expands Leadership Team with the Appointment of Rizwan Velji as Chief Business Officer

December 06, 2023

From Alentis Therapeutics

Via Business Wire

Alentis Therapeutics Doses First ANCA-Associated Vasculitis Rapidly Progressive Glomerulonephritis Patient in Phase 2 Clinical Trial of Lixudebart (ALE.F02)

December 05, 2023

From Alentis Therapeutics

Via Business Wire

Alentis Therapeutics Doses First Patient in Phase 1/2 Clinical Trial of ALE.C04 in Head and Neck Squamous Cell Carcinoma (HNSCC)

November 16, 2023

From Alentis Therapeutics

Via Business Wire

Alentis Therapeutics Appoints Lung Experts Professors Tony Mok and Steven Nathan to its Scientific Advisory Board

October 05, 2023

From Alentis Therapeutics

Via Business Wire

Alentis Therapeutics to Present at the European Respiratory Society (ERS) International Congress

August 29, 2023

From Alentis Therapeutics

Via Business Wire

Alentis Therapeutics Receives FDA Fast Track Designation for ALE.C04 for the Treatment of Claudin-1 Positive HNSCC

August 24, 2023

From Alentis Therapeutics

Via Business Wire

Alentis Therapeutics Appoints Luca Santarelli as Chairperson

June 29, 2023

From Alentis Therapeutics

Via Business Wire

Alentis Therapeutics Appoints Prof. David Jayne and Prof. Josep Tabernero to its Scientific Advisory Board

June 21, 2023

From Alentis Therapeutics

Via Business Wire

Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors

June 14, 2023

From Alentis Therapeutics

Via Business Wire

Alentis Therapeutics Reports Positive Topline Results From Phase 1 Multiple-ascending Dose Cohorts Study

April 26, 2023

From Alentis Therapeutics

Via Business Wire

Alentis Therapeutics Closes $105 Million Series C Funding to Advance Transformational Medicines for Claudin-1

April 13, 2023

From Alentis Therapeutics

Via Business Wire

Positive Results from Single Ascending Dose Phase 1 Study of ALE.F02 Targeting Claudin-1

January 09, 2023

From Alentis Therapeutics

Via Business Wire

Alentis Therapeutics Appoints Dr. Andrea Pellacani as Chief Medical Officer

May 03, 2022

From Alentis Therapeutics

Via Business Wire

Alentis Therapeutics Starts First-in-Human Clinical Trial for the Treatment of Liver and Kidney Fibrosis

January 04, 2022

From Alentis Therapeutics

Via Business Wire

Alentis Therapeutics Announces Appointments of Luca Santarelli to the Board of Directors and Rafaèle Tordjman as Chairperson

November 09, 2021

From Alentis Therapeutics

Via Business Wire

Alentis Therapeutics Raises USD 67 Million in Series B Financing

June 15, 2021

From Alentis Therapeutics

Via Business Wire

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.